Se connecter Inscription gratuite

4SC AG BPA

Quel est le BPA de 4SC AG?

Le BPA de 4SC AG est -0.41

Quelle est la définition de BPA?



Le bénéfice par action (BPA) est la partie du bénéfice d’une société affectée à chaque action en circulation d’actions ordinaires. Il est ajusté pour tenir compte de la dilution et calculé sur douze mois.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

BPA des entreprises dans Health Care secteur sur XETRA par rapport à 4SC AG

Que fait 4SC AG?

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.

Entreprises avec bpa similaire à 4SC AG